摘要
艾加莫德α是一种新生儿Fc受体(FcRn)拮抗剂,可通过与FcRn结合并抑制其与IgG的相互作用,显著降低病理性乙酰胆碱受体(AChR)抗体在内的血清IgG水平。2023年6月30日,中国国家药品监督管理局批准艾加莫德α注射液在中国上市,用于治疗AChR抗体阳性的成人全身型重症肌无力。本文就其作用机制、药动学、有效性及安全性等方面进行综述,旨在为其临床用药提供参考。
Efgartigimod alfa is a neonatal Fc receptor(FcRn)antagonist that significantly reduces serum IgG levels,in‐cluding pathological acetylcholine receptor(AChR)antibodies,by binding to FcRn and inhibiting its interaction with IgG.On 30 June 2023,the National Medical Products Administration(NMPA)of China approved the marketing of efgartigimod alfa in‐jection for the treatment of AChR antibody-positive adults with generalized myasthenia gravis(gMG).This article reviews its mechanism of action,pharmacokinetics,efficacy,and safety,aiming to provide a reference for its clinical application.
作者
李健春
陈頔
曹炜航
金鹏飞
LI Jian-chun;CHEN Di;CAO Wei-hang;JIN Peng-fei(Department of Pharmacy,Beijing Hospital,National Center of Gerontology,Institute of Geriatric Medicine,Chinese Academy of Medical Sciences,Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application(Beijing Hospital),Beijing 100730,China;Department of Pharmacy Administration and Clinical Pharmacy,School of Pharmaceutical Sciences,Peking University,Beijing 100191,China)
出处
《临床药物治疗杂志》
2024年第4期21-25,共5页
Clinical Medication Journal
